KR20120081120A - 뉴로키닌 2 수용체 활성과 관련된 장애 또는 질환을 치료하기 위한 화합물 - Google Patents

뉴로키닌 2 수용체 활성과 관련된 장애 또는 질환을 치료하기 위한 화합물 Download PDF

Info

Publication number
KR20120081120A
KR20120081120A KR1020127008768A KR20127008768A KR20120081120A KR 20120081120 A KR20120081120 A KR 20120081120A KR 1020127008768 A KR1020127008768 A KR 1020127008768A KR 20127008768 A KR20127008768 A KR 20127008768A KR 20120081120 A KR20120081120 A KR 20120081120A
Authority
KR
South Korea
Prior art keywords
compound
disorder
pharmaceutically acceptable
receptor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127008768A
Other languages
English (en)
Korean (ko)
Inventor
제랄드 베인
조엘 사다보이
하오 첸
시아오유 쉔
Original Assignee
유나이티드 파라곤 어소시에이츠 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유나이티드 파라곤 어소시에이츠 인크. filed Critical 유나이티드 파라곤 어소시에이츠 인크.
Publication of KR20120081120A publication Critical patent/KR20120081120A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020127008768A 2009-09-04 2010-09-07 뉴로키닌 2 수용체 활성과 관련된 장애 또는 질환을 치료하기 위한 화합물 Withdrawn KR20120081120A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24001409P 2009-09-04 2009-09-04
US61/240,014 2009-09-04

Publications (1)

Publication Number Publication Date
KR20120081120A true KR20120081120A (ko) 2012-07-18

Family

ID=43649685

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127008768A Withdrawn KR20120081120A (ko) 2009-09-04 2010-09-07 뉴로키닌 2 수용체 활성과 관련된 장애 또는 질환을 치료하기 위한 화합물

Country Status (14)

Country Link
US (1) US20120190743A1 (https=)
EP (1) EP2473038A4 (https=)
JP (1) JP2013503908A (https=)
KR (1) KR20120081120A (https=)
CN (1) CN102740693A (https=)
AU (1) AU2010289276A1 (https=)
BR (1) BR112012004988A2 (https=)
CA (1) CA2773035A1 (https=)
MX (1) MX2012002551A (https=)
NZ (1) NZ599215A (https=)
RU (1) RU2012112943A (https=)
SG (1) SG178964A1 (https=)
WO (1) WO2011029099A1 (https=)
ZA (1) ZA201202492B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508180A1 (en) * 2011-04-04 2012-10-10 Nestec S.A. Sn-1(3) Monoacylglycerides and lipid absorption
JP6570521B2 (ja) 2013-08-01 2019-09-04 ディグニファイ セラピューティクス エルエルシー 排尿及び排便を誘発するための組成物及び方法
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001A (en) * 1838-11-09 Open grate fobj burning coai
GB820954A (en) * 1956-05-02 1959-09-30 Beecham Res Lab Improvements in or relating to esters of 2,3-dimercaptopropanol
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS505309A (https=) * 1973-05-28 1975-01-21
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
JPH02131418A (ja) * 1988-11-10 1990-05-21 Sansho Seiyaku Co Ltd 外用剤
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4204151A1 (de) * 1992-02-12 1993-08-19 Schneider Manfred Prof Dr Regioisomerenreine monoglyceride sowie ein verfahren zu ihrer herstellung durch enzymatische veresterung von glycerin in organischen loesungsmitteln
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JPH0931020A (ja) * 1995-07-25 1997-02-04 Soda Koryo Kk グリセロールモノ−６−ヒドロキシアルカン酸エステル、及びこれを含有する香料組成物
SE9604582D0 (sv) * 1996-12-13 1996-12-13 Astra Ab Novel compounds
EP1230207B1 (en) * 1999-11-18 2005-06-22 Richard L. Pederson Metathesis syntheses of pheromones or their components
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
CN1286529C (zh) * 2004-06-11 2006-11-29 华中科技大学 具有皮肤靶向性的药物组合物及其制备方法和用途
US7906147B2 (en) * 2006-10-12 2011-03-15 Nanoprobes, Inc. Functional associative coatings for nanoparticles
BRPI0906484A2 (pt) * 2008-01-11 2017-06-13 United Paragon Ass Inc isolado de ovo fertilizado e seus usos

Also Published As

Publication number Publication date
RU2012112943A (ru) 2013-10-10
CA2773035A1 (en) 2011-03-10
JP2013503908A (ja) 2013-02-04
NZ599215A (en) 2014-11-28
SG178964A1 (en) 2012-04-27
BR112012004988A2 (pt) 2015-09-08
EP2473038A4 (en) 2013-10-23
WO2011029099A1 (en) 2011-03-10
CN102740693A (zh) 2012-10-17
AU2010289276A1 (en) 2012-05-03
US20120190743A1 (en) 2012-07-26
ZA201202492B (en) 2013-02-27
MX2012002551A (es) 2012-09-07
EP2473038A1 (en) 2012-07-11

Similar Documents

Publication Publication Date Title
JP7727733B2 (ja) 薬学的活性化合物としてのカンナビノイド誘導体及びその調製方法
JP4993523B2 (ja) ２０（ｓ）−プロトパナキサジオールの抗うつ薬製造への使用
JP7033642B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
AU2021215274B2 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
TW201138759A (en) Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
RU2678571C1 (ru) Терапевтическое и/или профилактическое средство, содержащее производное 1-индансульфамида, против боли
JP6068457B2 (ja) 化合物及び組成物
TW201622728A (zh) 全身紅斑性狼瘡之治療
JP2009520032A (ja) 脂質を低下させかつ血糖値を低下させるためのベンゾ縮合複素環スルファミド誘導体の使用
JP2002502375A (ja) 脳アミロイドーシスを治療するための薬物
KR20120081120A (ko) 뉴로키닌 2 수용체 활성과 관련된 장애 또는 질환을 치료하기 위한 화합물
AU2007224438A1 (en) Autoimmune conditions and NADPH oxidase defects
JP6262096B2 (ja) 受精卵分離物およびその使用
HK1177391A (en) Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
CN110003157A (zh) 一种具有抗焦虑作用的新型黄酮类化合物及其应用
CN1678300A (zh) 可用于治疗慢性髓细胞性白血病的药物组合物
JP2025500813A (ja) カンナビジオール誘導体、その調製方法及び使用
JP2015500804A (ja) オプシン結合性リガンド、組成物、及び使用方法
HK1153395A (en) Fertilized egg isolate and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120404

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid